Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Phase III Trial of (LCT) After Nivolumab and Ipilimumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03391869
Recruitment Status : Recruiting
First Posted : January 5, 2018
Last Update Posted : December 10, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This phase III trial studies how well nivolumab and ipilimumab works with or without local consolidation therapy in treating patients with stage IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Local consolidation therapy, such as surgery or radiation therapy, may improve survival outcomes in patients with non-small cell lung cancer. It is not yet known whether giving nivolumab and ipilimumab with local consolidation therapy works better than nivolumab and ipilimumab alone in treating patients with stage IV non-small cell lung cancer.

Condition or disease Intervention/treatment Phase
Lung Adenocarcinoma Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Biological: Ipilimumab Procedure: Local Consolidation Therapy Biological: Nivolumab Other: Quality-of-Life Assessment Radiation: Radiation Therapy Procedure: Therapeutic Conventional Surgery Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 270 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS
Actual Study Start Date : December 29, 2017
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm A (ipilimumab, nivolumab)

INDUCTION PHASE: Patients receive nivolumab IV over 90 minutes on days 1, 15, and 29, and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.

Patients receive nivolumab IV over 60 minutes on days 1, 15, and 29 and ipilimumab IV over 90 minutes on day 1. Courses repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

Biological: Ipilimumab
Given IV
Other Names:
  • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
  • Yervoy

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Experimental: Arm B (ipilimumab, nivolumab, LCT)

INDUCTION PHASE: Patients receive nivolumab IV over 90 minutes on days 1, 15, and 29, and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.

Patients receive LCT consisting of surgery and/or radiation 14 days after completion of Induction Phase. Patients then receive nivolumab and ipilimumab as in arm A beginning within 4 weeks after LCT. Courses repeat every 6 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

Biological: Ipilimumab
Given IV
Other Names:
  • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
  • BMS-734016
  • MDX-010
  • MDX-CTLA4
  • Yervoy

Procedure: Local Consolidation Therapy
Undergo radiation and/or surgery
Other Names:
  • LCT
  • Local Consolidative Therapy

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Radiation: Radiation Therapy
Undergo radiation
Other Names:
  • Cancer Radiotherapy
  • Irradiate
  • Irradiated
  • irradiation
  • Radiation
  • Radiation Therapy, NOS
  • Radiotherapeutics
  • RADIOTHERAPY
  • RT
  • Therapy, Radiation

Procedure: Therapeutic Conventional Surgery
Undergo surgery




Primary Outcome Measures :
  1. Overall survival (OS) in overall population [ Time Frame: Up to 1 year after completion of study treatment ]
    The type I error of 0.10 for the entire study is divided in half (0.10/2 = 0.05) allowing for a Type I error of 0.05 for each of the efficacy endpoints.

  2. OS in oligometastatic subgroup [ Time Frame: Up to 1 year after completion of study treatment ]
    The assessment for the subpopulation of patients with oligometastatic disease will be conducted only if the finding in the total population is found to be non-significant. The type I error of 0.10 for the entire study is divided in half (0.10/2 = 0.05) allowing for a Type I error of 0.05 for each of the efficacy endpoints described above.


Secondary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: up to 2 years ]
    Progression-free survival (PFS) determined from randomization to the earliest of the three endpoints: a) progression, b) last imaging study, or c) death Progression measured using RECIST 1.1 criteria.

  2. Time to Appearance of New Metastases (TANM) [ Time Frame: up to 2 years ]
    Time to appearance of new metastases (TANM) determined from randomization to the earliest of the two endpoints: a) development of a new lesion, or b) last imaging study per RECIST 1.1 criteria.

  3. Progression of Target lesions Defined by RECIST 1.1 Criteria [ Time Frame: up to 2 years ]
  4. Progression of Non-Target Lesions by RECIST 1.1 Criteria [ Time Frame: up to 2 years ]
  5. Toxicity Evaluated Using CTCAE v4.0 Criteria [ Time Frame: up to 2 years ]
    Toxicity evaluated using CTCAE v4.0 criteria, with a specific focus on ≥3 toxicity.

  6. Quality of Life (QOL) [ Time Frame: After 12 weeks of therapy and then every 3 months for up to 2 years ]
    QOL assessed using the lung-MD Anderson symptom inventory (MDASI-LC) questionnaire in collaboration with the MD Anderson symptom management group, at the following timepoints: 1) prior to induction treatment, 2) prior to randomization, 3) every 12 weeks, and 4) after progression/off study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed non-small cell lung cancer; if a diagnostic biopsy is available, a pre-treatment biopsy is not required. Patients with a suspected lung cancer may be consented, but pathology must be confirmed prior to initiating treatment on study. Neuroendocrine carcinomas (e.g. small cell lung cancer [SCLC], carcinoid tumors) are not eligible. Carcinomas with neuroendocrine differentiation are eligible.
  • Stage IV (according to the American Joint Committee on Cancer [AJCC] 8th edition).
  • Signed and dated written informed consent prior to admission to the study in accordance with International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines and to the local legislation.
  • For lung adenocarcinoma patients, patients must not harbor any EGFR sensitizing or ALK fusion where there are standard care therapy options available. For patients with histologies other than adenocarcinoma, EGFR and ALK status is not required. Adenocarcinoma patients may be consented prior to the EGFR and ALK status being known, but EGFR and ALK status must be determined prior to initiating therapy. EGFR and ALK status may be determined using either tumor- or plasma-based, Clinical Laboratory Improvement Amendments (CLIA)-certified assays. For patients with non-small cell lung cancer (NSCLC), not otherwise specified (NOS), EGFR/ALK testing is not required, as the frequency of alterations is exceedingly rare in this histology. Also, note that patients with ROS1/RET alterations can be enrolled, as tyrosine kinase inhibitor such as crizotinib aren't established as first line therapy for patients with these alterations.
  • One prior line of chemotherapy and/or targeted agents for metastatic disease are permitted. This chemotherapy can include maintenance therapy, as long as it was given in the front line setting. In addition, prior antiangiogenic therapy (e.g. bevacizumab) is permitted if used as frontline treatment.
  • Performance status of 0 or 1 if using Eastern Cooperative Oncology Group (ECOG)/Zubrod.
  • White blood cell (WBC ) >= 2000/uL (obtained within 14 days prior to randomization/registration)
  • Neutrophils >= 1500/uL (obtained within 14 days prior to randomization/registration)
  • Platelets >= 100 x 10^3/uL (obtained within 14 days prior to randomization/registration)
  • Hemoglobin > 9.0 g/dL (obtained within 14 days prior to randomization/registration)
  • Serum creatinine =< 1.5 x upper limit of normal (ULN) or creatinine clearance (CrCl) >= 50 mL (if using the Cockcroft-Gault formula) (obtained within 14 days prior to randomization/registration)
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (obtained within 14 days prior to randomization/registration)
  • Total Bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL) (obtained within 14 days prior to randomization/registration)
  • Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. Appropriate methods of contraception are as follows. Women will be instructed to adhere to contraception for a period of 26 weeks after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 35 weeks after the last week of nivolumab/ipilimumab (nivo/ipi). Note: WOCBP is defined as any female who has experienced menarche and who has not yet undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented negative serum or urine test.
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 48 hours prior to the start of nivolumab.
  • Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 35 weeks after the last dose of investigational product. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception.
  • Subjects with brain metastases are eligible if metastases are adequately treated and subjects are neurologically stable (except for residual signs or symptoms related to the central nervous system [CNS] treatment) for at least 2 weeks prior to the first dose of nivolumab. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of =< 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to the first dose of nivolumab. Patients with asymptomatic, small (e.g. =< 1 cm) brain metastases are 1)eligible
  • provided that the patient is off corticosteroids, or on a stable or decreasing dose of =< 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to the first dose of nivolumab
  • Subjects may receive radiotherapy for symptomatic metastases prior to enrollment provided that there is at least one other non-irradiated lesion amenable to LCT at the time of enrollment. When feasible, stereotactic body radiation therapy (SBRT) or other hypofractionated techniques are strongly encouraged.

Exclusion Criteria:

  • Systemic immunotherapy for metastatic NSCLC. Immunotherapy agents include, but are not limited to, agents targeting the PD1/PD-L1 axis (e.g. nivolumab, pembrolizumab, atezolizumab, durvalumab) or CTLA-4 (ipilimumab, tremelimumab) pathways.
  • Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to the initiation of study treatment. The following exceptions are allowed: hormone-replacement therapy or oral contraceptives
  • Women must not be breastfeeding.
  • Patients excluded with prior treatment of pneumonitis requiring corticosteroids within 60 days prior to the first dose of nivolumab
  • Unwillingness or inability to follow the procedures required in the protocol.
  • Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
  • Prior malignancy active within the previous 2 years. Patients with locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast with local control measures (surgery, radiation) are eligible.
  • Patients should be excluded if they have an active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
  • Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration (i.e. disease-modifying antirheumatic drugs). Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Note that subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if >10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g. contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by contact allergen) is permitted.
  • As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution.
  • Patients should be excluded if they are known to be positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
  • Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
  • History of allergy to study drug components.
  • History of severe hypersensitivity reaction to any monoclonal antibody.
  • Prisoners or subjects who are involuntarily incarcerated.
  • Subjects who are compulsorily detained for treatment of either a psychiatric or physical (infection disease) illness.
  • Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule.
  • Any condition that, in the opinion of the investigator, would interfere with the study treatment or interpretation of the study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03391869


Contacts
Layout table for location contacts
Contact: John Heymach, MD, PHD 713-792-6363 jheymach@mdanderson.org

Locations
Layout table for location information
United States, Texas
MD Anderson in The Woodlands Not yet recruiting
Conroe, Texas, United States, 77384
Contact: John V. Heymach    713-792-6363      
Principal Investigator: John V. Heymach         
Memorial Hermann Memorial City Medical Center Not yet recruiting
Houston, Texas, United States, 77024
Contact: John V. Heymach    713-792-6363      
Principal Investigator: John V. Heymach         
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: John V. Heymach    713-792-6363      
Principal Investigator: John V. Heymach         
MD Anderson West Houston Not yet recruiting
Houston, Texas, United States, 77079
Contact: John V. Heymach    713-792-6363      
Principal Investigator: John V. Heymach         
MD Anderson League City Not yet recruiting
League City, Texas, United States, 77573
Contact: John V. Heymach    713-792-6363      
Principal Investigator: John V. Heymach         
MD Anderson in Sugar Land Not yet recruiting
Sugar Land, Texas, United States, 77478
Contact: John V. Heymach    713-792-6363      
Principal Investigator: John V. Heymach         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: John V Heymach M.D. Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT03391869    
Other Study ID Numbers: 2017-0311
NCI-2018-00825 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2017-0311 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
First Posted: January 5, 2018    Key Record Dates
Last Update Posted: December 10, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Adenocarcinoma
Adenocarcinoma of Lung
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Bronchogenic
Bronchial Neoplasms
Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents